Patients with HRD-related gene mutations are often sensitive to PARP inhibitors, so we proposed that SLC26A4 may be a novel biomarker to screen patients sensitive to PARP inhibitors. The gene discussed is SLC26A4; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.